A Study of BL-B01D1 in Patients With Multiple Solid Tumors, Including Locally Advanced or Metastatic Urinary System Tumors
A phase 2 trial of BL-B01D1 in advanced solid tumours, run by Sichuan Baili Pharmaceutical Co., Ltd., now recruiting.
Overview
A Study of BL-B01D1 in Patients With Multiple Solid Tumors, Including Locally Advanced or Metastatic Urinary System Tumors is a phase 2 interventional study registered as NCT05785039 by Sichuan Baili Pharmaceutical Co., Ltd., with 76 participants planned, started 2023-04-20 and due to reach its primary completion in 2026-12. Interventions recorded: BL-B01D1.
Similar pages
not linked directly; found by shared links- TrialA Study of BL-B01D1 in Patients With Multiple Solid Tumors, Including Recurrent or Metastatic Gynecological Malignancies
Shares SystImmune / Sichuan Biokin, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA Study of BL-M07D1 in Patients With a Variety of Solid Tumors Including Locally Advanced or Metastatic HER2-positive/Low-expressing Urinary and Gastrointestinal Tumors
Shares SystImmune / Sichuan Biokin, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA Study of SI-B003 or BL-B01D1+SI-B003 in Patients With Unresectable Locally Advanced or Recurrent Metastatic HER2 Negative Breast Cancer
Shares SystImmune / Sichuan Biokin, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA Study of BL-M07D1 in Patients With HER2-expressing Recurrent or Metastatic Gynecologic Malignancies
Shares SystImmune / Sichuan Biokin, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced, Recurrent, or Metastatic HR+/HER2- Breast Cancer After Failure of Prior Endocrine Therapy(PANKU-Breast03)
Shares SystImmune / Sichuan Biokin, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA Study of BL-M02D1 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer or Other Solid Tumors
Shares SystImmune / Sichuan Biokin and the tag pipeline.
- TrialA Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Unresectable Locally Advanced or Recurrent Metastatic Triple-negative Breast Cancer
Shares SystImmune / Sichuan Biokin and the tag pipeline.
- TrialA Study of GNC-038, a Tetra-specific Antibody, in Participants With R/R Diffuse Large B-cell Lymphoma (DLBCL)
Shares SystImmune / Sichuan Biokin and the tag pipeline.